The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

Some drugs can activate AMPK, most prominently metformin, which is approved for diabetes and being trialed in dementia. Less well-known is aldometanib, developed by Lin’s team, which blocks aldolase, ...

This cross-sectional study showed websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially informed and sometimes misinformed potential consumers. Compounded ...

Objective. Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents ...

glucagon-like peptide-1; DLK1, delta like-1; WoS, Web of Science; WoSCC, Web of science core collection; JIC, Journal Citation Indicator; TC, total citation; BMP7, Bone Morphogenetic Protein 7; RANKL, ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online January ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders.

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Study of 2.4 million participants reveals potential advantages for cardiometabolic and psychiatric conditions alongside increased risks of gastrointestinal and musculoskeletal issues Study ...